Trajectories of daily antipsychotic use and weight gain in people hospitalized for the first episode of psychosis.
Humans
Antipsychotic Agents
/ therapeutic use
Weight Gain
/ drug effects
Female
Male
Psychotic Disorders
/ drug therapy
Adult
Hospitalization
/ statistics & numerical data
Body Mass Index
Schizophrenia
/ drug therapy
Young Adult
Risperidone
/ therapeutic use
Olanzapine
/ therapeutic use
Polypharmacy
Prospective Studies
Risk Factors
antipsychotics
polypharmacy
predictor
schizophrenia
weight gain
Journal
European psychiatry : the journal of the Association of European Psychiatrists
ISSN: 1778-3585
Titre abrégé: Eur Psychiatry
Pays: England
ID NLM: 9111820
Informations de publication
Date de publication:
26 Sep 2024
26 Sep 2024
Historique:
medline:
26
9
2024
pubmed:
26
9
2024
entrez:
26
9
2024
Statut:
epublish
Résumé
We need to better understand the risk factors and predictors of medication-related weight gain to improve metabolic health of individuals with schizophrenia. This study explores how trajectories of antipsychotic medication (AP) use impact body weight early in the course of schizophrenia. We recruited 92 participants with first-episode psychosis (FEP, Most people started treatment with risperidone ( Early in the course of illness, during inpatient treatment, baseline BMI is the strongest and earliest predictor of weight gain on APs and is a better predictor than type of medication, polypharmacy, or medication switches. Baseline BMI predicted weight change over a period of weeks, when other traditional predictors demonstrated a much smaller effect.
Sections du résumé
BACKGROUND
BACKGROUND
We need to better understand the risk factors and predictors of medication-related weight gain to improve metabolic health of individuals with schizophrenia. This study explores how trajectories of antipsychotic medication (AP) use impact body weight early in the course of schizophrenia.
METHODS
METHODS
We recruited 92 participants with first-episode psychosis (FEP,
RESULTS
RESULTS
Most people started treatment with risperidone (
CONCLUSIONS
CONCLUSIONS
Early in the course of illness, during inpatient treatment, baseline BMI is the strongest and earliest predictor of weight gain on APs and is a better predictor than type of medication, polypharmacy, or medication switches. Baseline BMI predicted weight change over a period of weeks, when other traditional predictors demonstrated a much smaller effect.
Identifiants
pubmed: 39323217
doi: 10.1192/j.eurpsy.2024.1761
pii: S0924933824017619
doi:
Substances chimiques
Antipsychotic Agents
0
Risperidone
L6UH7ZF8HC
Olanzapine
N7U69T4SZR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e59Subventions
Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : NV16-32791A